SiRNAmod: A database of experimentally validated chemically modified siRNAs

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Dar, Showkat Ahmad ^a   Thakur, Anamika ^a   Qureshi, Abid ^a   Kumar, Manoj ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA;

BIOLOGY; CHEMISTRY; GENETIC DATABASE; GENETICS; HUMAN; PROCEDURES; SOFTWARE; WEB BROWSER;

COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; HUMANS; RNA, SMALL INTERFERING; SOFTWARE; WEB BROWSER;

EID: 84956528338     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20031     Document Type: Article

References (58)

1. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811, doi: 10.1038/35888 (1998).
2. Woessmann, W., Damm-Welk, C., Fuchs, U. & Borkhardt, A. RNA interference: new mechanisms for targeted treatment? Reviews in clinical and experimental hematology 7, 270-291 (2003).
3. Filipowicz, W. RNAi: the nuts and bolts of the RISC machine. Cell 122, 17-20, doi: 10.1016/j.cell.2005.06.023 (2005).
4. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070, doi: 10.1038/nature08956 (2010).
5. Joo, M. K., Yhee, J. Y., Kim, S. H. & Kim, K. The potential and advances in RNAi therapy: Chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers. Journal of controlled release : official journal of the Controlled Release Society, doi: 10.1016/j.jconrel.2014.05.030 (2014).
6. Gallas, A., Alexander, C., Davies, M. C., Puri, S. & Allen, S. Chemistry and formulations for siRNA therapeutics. Chemical Society reviews 42, 7983-7997, doi: 10.1039/c3cs35520a (2013).
7. Gaglione, M. & Messere, A. Recent progress in chemically modified siRNAs. Mini reviews in medicinal chemistry 10, 578-595 (2010).
8. Stephenson, M. L. & Zamecnik, P. C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proceedings of the National Academy of Sciences of the United States of America 75, 285-288 (1978).
9. Wilson, C. & Keefe, A. D. Building oligonucleotide therapeutics using non-natural chemistries. Current opinion in chemical biology 10, 607-614, doi: 10.1016/j.cbpa.2006.10.001 (2006).
10. Elmen, J. et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic acids research 33, 439-447, doi: 10.1093/nar/gki193 (2005).
11. Kenski, D. M. et al. Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5′-terminal phosphorylation both in vitro and in vivo. Nucleic acids research 38, 660-671, doi: 10.1093/nar/gkp913 (2010).
12. Takahashi, M. et al. Intracellular stability of 2′-OMe-4′-thioribonucleoside modified siRNA leads to long-term RNAi effect. Nucleic acids research 40, 5787-5793, doi: 10.1093/nar/gks204 (2012).
13. Prakash, T. P. et al. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. Journal of medicinal chemistry 48, 4247-4253, doi: 10.1021/jm050044o (2005).
14. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178, doi: 10.1038/nature03121 (2004).
15. Petersen, M. & Wengel, J. LNA: a versatile tool for therapeutics and genomics. Trends in biotechnology 21, 74-81, doi: 10.1016/S0167-7799(02)00038-0 (2003).
16. Grunweller, A. et al. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic acids research 31, 3185-3193 (2003).
17. Glud, S. Z. et al. Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides 19, 163-168, doi: 10.1089/oli.2008.0175 (2009).
18. Langkjaer, N., Pasternak, A. & Wengel, J. UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorganic & medicinal chemistry 17, 5420-5425, doi: 10.1016/j.bmc.2009.06.045 (2009).
19. Aboul-Fadl, T. Antisense oligonucleotides: the state of the art. Current medicinal chemistry 12, 2193-2214 (2005).
20. Detzer, A. & Sczakiel, G. Phosphorothioate-stimulated uptake of siRNA by mammalian cells: a novel route for delivery. Current topics in medicinal chemistry 9, 1109-1116 (2009).
21. Chiu, Y. L. & Rana, T. M. siRNA function in RNAi: a chemical modification analysis. Rna 9, 1034-1048 (2003).
22. Layzer, J. M. et al. In vivo activity of nuclease-resistant siRNAs. Rna 10, 766-771 (2004).
23. Odadzic, D. et al. Synthesis of 2′-O-modified adenosine building blocks and application for RNA interference. Bioorganic & medicinal chemistry 16, 518-529, doi: 10.1016/j.bmc.2007.09.019 (2008).
24. Bramsen, J. B. et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic acids research 37, 2867-2881, doi: 10.1093/nar/gkp106 (2009).
25. Somoza, A., Silverman, A. P., Miller, R. M., Chelliserrykattil, J. & Kool, E. T. Steric effects in RNA interference: probing the influence of nucleobase size and shape. Chemistry 14, 7978-7987, doi: 10.1002/chem.200800837 (2008).
26. Sipa, K. et al. Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. Rna 13, 1301-1316, doi: 10.1261/rna.538907 (2007).
27. Peacock, H., Kannan, A., Beal, P. A. & Burrows, C. J. Chemical modification of siRNA bases to probe and enhance RNA interference. The Journal of organic chemistry 76, 7295-7300, doi: 10.1021/jo2012225 (2011).
28. Hall, A. H., Wan, J., Shaughnessy, E. E., Ramsay Shaw, B. & Alexander, K. A. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic acids research 32, 5991-6000, doi: 10.1093/nar/gkh936 (2004).
29. Potenza, N. et al. RNA interference in mammalia cells by RNA-3′-PNA chimeras. International journal of molecular sciences 9, 299-315 (2008).
30. Detzer, A., Overhoff, M., Mescalchin, A., Rompf, M. & Sczakiel, G. Phosphorothioate-stimulated cellular uptake of siRNA: a cell culture model for mechanistic studies. Current pharmaceutical design 14, 3666-3673 (2008).
31. Braasch, D. A. et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorganic & medicinal chemistry letters 14, 1139-1143, doi: 10.1016/j.bmcl.2003.12.074 (2004).
32. Butora, G. et al. Nucleoside optimization for RNAi: a high-throughput platform. Journal of the American Chemical Society 133, 16766-16769, doi: 10.1021/ja2068774 (2011).
33. Broering, R. et al. Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. International immunology 26, 35-46, doi: 10.1093/intimm/dxt040 (2014).
34. Ren, Y. et al. siRecords: a database of mammalian RNAi experiments and efficacies. Nucleic acids research 37, D146-149, doi: 10.1093/nar/gkn817 (2009).
35. Chalk, A. M., Warfinge, R. E., Georgii-Hemming, P. & Sonnhammer, E. L. siRNAdb: a database of siRNA sequences. Nucleic acids research 33, D131-134, doi: 10.1093/nar/gki136 (2005).
36. Truss, M. et al. HuSiDa-the human siRNA database: an open-access database for published functional siRNA sequences and technical details of efficient transfer into recipient cells. Nucleic acids research 33, D108-111, doi: 10.1093/nar/gki131 (2005).
37. Thakur, N., Qureshi, A. & Kumar, M. VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA. Nucleic acids research 40, D230-236, doi: 10.1093/nar/gkr1147 (2012).
38. Tyagi, A. et al. HIVsirDB: a database of HIV inhibiting siRNAs. PloS one 6, e25917, doi: 10.1371/journal.pone.0025917 (2011).
39. Cantara, W. A. et al. The RNA Modification Database, RNAMDB: 2011 update. Nucleic acids research 39, D195-201, doi: 10.1093/nar/gkq1028 (2011).
40. Herraez, A. Biomolecules in the computer: Jmol to the rescue. Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology 34, 255-261, doi: 10.1002/bmb.2006.494034042644 (2006).
41. Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K. & Lopez-Berestein, G. Preclinical and clinical development of siRNA-based therapeutics. Advanced drug delivery reviews, doi: 10.1016/j.addr.2015.01.007 (2015).
42. Burnett, J. C., Rossi, J. J. & Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnology journal 6, 1130-1146, doi: 10.1002/biot.201100054 (2011).
43. Lares, M. R., Rossi, J. J. & Ouellet, D. L. RNAi and small interfering RNAs in human disease therapeutic applications. Trends in biotechnology 28, 570-579, doi: 10.1016/j.tibtech.2010.07.009 (2010).
44. Engels, J. W. Gene silencing by chemically modified siRNAs. New biotechnology 30, 302-307, doi: 10.1016/j.nbt.2012.07.002 (2013).
45. Turner, J. J., Jones, S. W., Moschos, S. A., Lindsay, M. A. & Gait, M. J. MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Molecular bioSystems 3, 43-50, doi: 10.1039/b611612d (2007).
46. Bramsen, J. B. & Kjems, J. Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering. Frontiers in genetics 3, 154, doi: 10.3389/fgene.2012.00154 (2012).
47. Foster, D. J. et al. Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo. Rna 18, 557-568, doi: 10.1261/rna.031120.111 (2012).
48. Nallagatla, S. R. & Bevilacqua, P. C. Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. Rna 14, 1201-1213, doi: 10.1261/rna.1007408 (2008).
49. Haringsma, H. J. et al. mRNA knockdown by single strand RNA is improved by chemical modifications. Nucleic acids research 40, 4125-4136, doi: 10.1093/nar/gkr1301 (2012).
50. Collingwood, M. A. et al. Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides 18, 187-200, doi: 10.1089/oli.2008.0123 (2008).
51. Somoza, A., Terrazas, M. & Eritja, R. Modified siRNAs for the study of the PAZ domain. Chemical communications 46, 4270-4272, doi: 10.1039/c003221b (2010).
52. Peel, B. J., Hagen, G., Krishnamurthy, K. & Desaulniers, J. P. Conjugation and Evaluation of Small Hydrophobic Molecules to Triazole-Linked siRNAs. ACS medicinal chemistry letters 6, 117-122, doi: 10.1021/ml500260j (2015).
53. Kenski, D. M., Willingham, A. T., Haringsma, H. J., Li, J. J. & Flanagan, W. M. In vivo activity and duration of short interfering RNAs containing a synthetic 5′-phosphate. Nucleic acid therapeutics 22, 90-95, doi: 10.1089/nat.2011.0333 (2012).
54. Kamiya, Y. et al. Enhancement of stability and activity of siRNA by terminal substitution with serinol nucleic acid (SNA). Chembiochem : a European journal of chemical biology 15, 2549-2555, doi: 10.1002/cbic.201402369 (2014).
55. Huang, Y. et al. Exploring directional invasion of serum nuclease into siRNA duplexes by asymmetrical terminal modifications. ChemMedChem 9, 2111-2119, doi: 10.1002/cmdc.201402115 (2014).
56. Hamada, M. et al. Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense & nucleic acid drug development 12, 301-309, doi: 10.1089/108729002761381285 (2002).
57. Amarzguioui, M., Holen, T., Babaie, E. & Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic acids research 31, 589-595 (2003).
58. Wang, Y. et al. PubChem BioAssay: 2014 update. Nucleic acids research 42, D1075-1082, doi: 10.1093/nar/gkt978 (2014).